Therapy Name | Mesothelin CAR-T cells |
Therapy Description |
Mesothelin CAR-T cells are T-cells that have been modified to express a chimeric antigen receptor targeting Mesothelin (MSLN), which may result in decreased growth of MSLN-expressing tumors, upon delivery (PMID: 22127019). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Mesothelin CAR-T cells | Mesothelin CAR-T cells are T-cells that have been modified to express a chimeric antigen receptor targeting Mesothelin (MSLN), which may result in decreased growth of MSLN-expressing tumors, upon delivery (PMID: 22127019). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status |
---|---|---|---|---|
NCT02792114 | Phase I | Rimiducid Mesothelin CAR-T cells Cyclophosphamide | T-Cell Therapy for Advanced Breast Cancer | Recruiting |